Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Cancer × Dasatinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21 Leukemia, Myeloid, Chronic-Phase 12 Leukemia 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Prostatic Neoplasms 3 Recurrence 2 Neoplasms 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Bronchiolitis Obliterans Syndrome 2 Breast Neoplasms 2 Blast Crisis 2 Advanced Breast Cancer 2 Philadelphia Chromosome 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Indications Cancer 1 Hematologic Neoplasms 1 Glioblastoma 1 Advanced Cancer 1

Interventions

Nivolumab 13 linrodostat 5 Ipilimumab 5 relatlimab 3 Pemetrexed 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 regorafenib 2 abemaciclib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Gemcitabine 2 Capecitabine 2 ARRY-334543 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 trametinib 1 tislelizumab 1 sargramostim 1 ralimetinib 1 palifosfamide lysine 1 p38 Mitogen-Activated Protein Kinases 1 lirilumab 1 fluzoparib 1 fluorapacin 1 etirinotecan pegol 1 emibetuzumab 1 efatutazone 1 cemiplimab 1 bempegaldesleukin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated

295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡